ArticleEClinicalMedicine2025

Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial.

Daniel A Pollyea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.